Public Sector Pension Investment Board Buys 74,469 Shares of Certara, Inc. $CERT

Key Points

• The Public Sector Pension Investment Board increased its stake in Certara, Inc. by 27.3%, acquiring an additional 74,469 shares, and now owns 347,176 shares valued at approximately $3.44 million.
• Certara recently reported earnings per share of $0.07, missing analysts' estimates, but its revenue increased by 12.1% year-over-year, totaling $104.57 million.
• Equities analysts have a consensus rating of "Moderate Buy" for Certara, with a target price averaging $15.14, reflecting differing opinions on the stock's future performance.

Public Sector Pension Investment Board raised its stake in shares of Certara, Inc. (NASDAQ:CERT - Free Report) by 27.3% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 347,176 shares of the company's stock after buying an additional 74,469 shares during the period. Public Sector Pension Investment Board owned about 0.21% of Certara worth $3,437,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in CERT. Versant Capital Management Inc raised its stake in Certara by 218.8% during the 1st quarter. Versant Capital Management Inc now owns 2,719 shares of the company's stock valued at $27,000 after buying an additional 1,866 shares during the last quarter. Wells Fargo & Company MN raised its stake in Certara by 48.4% during the 4th quarter. Wells Fargo & Company MN now owns 3,208 shares of the company's stock valued at $34,000 after buying an additional 1,047 shares during the last quarter. Johnson Financial Group Inc. purchased a new stake in Certara during the 4th quarter valued at $47,000. Sterling Capital Management LLC raised its stake in Certara by 57.2% during the 4th quarter. Sterling Capital Management LLC now owns 7,209 shares of the company's stock valued at $77,000 after buying an additional 2,624 shares during the last quarter. Finally, Associated Banc Corp purchased a new stake in Certara during the 1st quarter valued at $101,000. 73.96% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities research analysts have recently commented on the company. Barclays upgraded Certara from an "equal weight" rating to an "overweight" rating and upped their price objective for the stock from $11.00 to $14.00 in a research note on Thursday, May 8th. UBS Group reduced their price objective on Certara from $17.50 to $15.00 and set a "buy" rating for the company in a research note on Thursday, August 7th. KeyCorp reduced their price objective on Certara from $18.00 to $15.00 and set an "overweight" rating for the company in a research note on Monday, July 14th. Morgan Stanley assumed coverage on Certara in a research note on Thursday, July 3rd. They issued an "equal weight" rating and a $16.00 price objective for the company. Finally, JMP Securities restated a "market perform" rating on shares of Certara in a research note on Tuesday, May 6th. Five analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $15.14.

Certara Price Performance

Certara stock traded up $0.70 during mid-day trading on Friday, hitting $11.47. The stock had a trading volume of 1,182,580 shares, compared to its average volume of 1,422,768. The firm has a market capitalization of $1.84 billion, a P/E ratio of 229.45 and a beta of 1.42. The company has a current ratio of 2.16, a quick ratio of 2.16 and a debt-to-equity ratio of 0.27. The firm's 50 day moving average is $10.80 and its 200 day moving average is $11.58. Certara, Inc. has a one year low of $8.64 and a one year high of $15.69.

Certara (NASDAQ:CERT - Get Free Report) last issued its earnings results on Wednesday, August 6th. The company reported $0.07 earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.03). The firm had revenue of $104.57 million during the quarter, compared to the consensus estimate of $104.14 million. Certara had a return on equity of 5.11% and a net margin of 1.97%.The company's quarterly revenue was up 12.1% on a year-over-year basis. During the same period in the prior year, the company posted $0.07 EPS. On average, sell-side analysts forecast that Certara, Inc. will post 0.28 earnings per share for the current fiscal year.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.